DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma Article Swipe
Thibaud Prawitz
,
Rakesh Popat
,
Attaya Suvannasankha
,
Grammati Sarri
,
Rachel Hughes
,
Feng Wang
,
Cosmina Hogea
,
Shannon Ferrante
,
Boris Gorsh
,
Jenny Willson
,
Venediktos Kapetanakis
·
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1007/s12325-021-01884-7
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1007/s12325-021-01884-7
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1007/s12325-021-01884-7
- https://link.springer.com/content/pdf/10.1007/s12325-021-01884-7.pdf
- OA Status
- hybrid
- Cited By
- 10
- References
- 25
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3200079942
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3200079942Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1007/s12325-021-01884-7Digital Object Identifier
- Title
-
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple MyelomaWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2021Year of publication
- Publication date
-
2021-09-24Full publication date if available
- Authors
-
Thibaud Prawitz, Rakesh Popat, Attaya Suvannasankha, Grammati Sarri, Rachel Hughes, Feng Wang, Cosmina Hogea, Shannon Ferrante, Boris Gorsh, Jenny Willson, Venediktos KapetanakisList of authors in order
- Landing page
-
https://doi.org/10.1007/s12325-021-01884-7Publisher landing page
- PDF URL
-
https://link.springer.com/content/pdf/10.1007/s12325-021-01884-7.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://link.springer.com/content/pdf/10.1007/s12325-021-01884-7.pdfDirect OA link when available
- Concepts
-
Medicine, Internal medicine, Dexamethasone, Hazard ratio, Carfilzomib, Refractory (planetary science), Confidence interval, Multiple myeloma, Adverse effect, Oncology, Gastroenterology, Lenalidomide, Astrobiology, PhysicsTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
10Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 2, 2024: 2, 2023: 3, 2022: 3Per-year citation counts (last 5 years)
- References (count)
-
25Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3200079942 |
|---|---|
| doi | https://doi.org/10.1007/s12325-021-01884-7 |
| ids.doi | https://doi.org/10.1007/s12325-021-01884-7 |
| ids.mag | 3200079942 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/34561812 |
| ids.openalex | https://openalex.org/W3200079942 |
| fwci | 1.48524913 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D061067 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[1].qualifier_ui | Q000627 |
| mesh[1].descriptor_ui | D000971 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | therapeutic use |
| mesh[1].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[2].qualifier_ui | Q000627 |
| mesh[2].descriptor_ui | D003907 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | therapeutic use |
| mesh[2].descriptor_name | Dexamethasone |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D006801 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Humans |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D006834 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Hydrazines |
| mesh[5].qualifier_ui | Q000188 |
| mesh[5].descriptor_ui | D009101 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | drug therapy |
| mesh[5].descriptor_name | Multiple Myeloma |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D009364 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Neoplasm Recurrence, Local |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D059039 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Standard of Care |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D014230 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Triazoles |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D061067 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[10].qualifier_ui | Q000627 |
| mesh[10].descriptor_ui | D000971 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | therapeutic use |
| mesh[10].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[11].qualifier_ui | Q000627 |
| mesh[11].descriptor_ui | D003907 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | therapeutic use |
| mesh[11].descriptor_name | Dexamethasone |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D006801 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Humans |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D006834 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Hydrazines |
| mesh[14].qualifier_ui | Q000188 |
| mesh[14].descriptor_ui | D009101 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | drug therapy |
| mesh[14].descriptor_name | Multiple Myeloma |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D009364 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Neoplasm Recurrence, Local |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D059039 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Standard of Care |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D014230 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Triazoles |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D061067 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[19].qualifier_ui | Q000627 |
| mesh[19].descriptor_ui | D000971 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | therapeutic use |
| mesh[19].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[20].qualifier_ui | Q000627 |
| mesh[20].descriptor_ui | D003907 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | therapeutic use |
| mesh[20].descriptor_name | Dexamethasone |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D006801 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Humans |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D006834 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Hydrazines |
| mesh[23].qualifier_ui | Q000188 |
| mesh[23].descriptor_ui | D009101 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | drug therapy |
| mesh[23].descriptor_name | Multiple Myeloma |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D009364 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Neoplasm Recurrence, Local |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D059039 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Standard of Care |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D014230 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Triazoles |
| type | article |
| title | DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma |
| biblio.issue | 11 |
| biblio.volume | 38 |
| biblio.last_page | 5518 |
| biblio.first_page | 5501 |
| topics[0].id | https://openalex.org/T10649 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2720 |
| topics[0].subfield.display_name | Hematology |
| topics[0].display_name | Multiple Myeloma Research and Treatments |
| topics[1].id | https://openalex.org/T12534 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9973999857902527 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | Protein Degradation and Inhibitors |
| topics[2].id | https://openalex.org/T12505 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.994700014591217 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Peptidase Inhibition and Analysis |
| is_xpac | False |
| apc_list.value | 3390 |
| apc_list.currency | EUR |
| apc_list.value_usd | 4390 |
| apc_paid.value | 3390 |
| apc_paid.currency | EUR |
| apc_paid.value_usd | 4390 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9177043437957764 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C126322002 |
| concepts[1].level | 1 |
| concepts[1].score | 0.6951285004615784 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[1].display_name | Internal medicine |
| concepts[2].id | https://openalex.org/C2780401358 |
| concepts[2].level | 2 |
| concepts[2].score | 0.6050716042518616 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q422252 |
| concepts[2].display_name | Dexamethasone |
| concepts[3].id | https://openalex.org/C207103383 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5647751092910767 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q3930246 |
| concepts[3].display_name | Hazard ratio |
| concepts[4].id | https://openalex.org/C2780108899 |
| concepts[4].level | 4 |
| concepts[4].score | 0.547812283039093 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q15366934 |
| concepts[4].display_name | Carfilzomib |
| concepts[5].id | https://openalex.org/C142424586 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5126182436943054 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q7307572 |
| concepts[5].display_name | Refractory (planetary science) |
| concepts[6].id | https://openalex.org/C44249647 |
| concepts[6].level | 2 |
| concepts[6].score | 0.512069046497345 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q208498 |
| concepts[6].display_name | Confidence interval |
| concepts[7].id | https://openalex.org/C2776364478 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4694152772426605 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q467635 |
| concepts[7].display_name | Multiple myeloma |
| concepts[8].id | https://openalex.org/C197934379 |
| concepts[8].level | 2 |
| concepts[8].score | 0.45947378873825073 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q2047938 |
| concepts[8].display_name | Adverse effect |
| concepts[9].id | https://openalex.org/C143998085 |
| concepts[9].level | 1 |
| concepts[9].score | 0.4411904811859131 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[9].display_name | Oncology |
| concepts[10].id | https://openalex.org/C90924648 |
| concepts[10].level | 1 |
| concepts[10].score | 0.41281723976135254 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[10].display_name | Gastroenterology |
| concepts[11].id | https://openalex.org/C2776063141 |
| concepts[11].level | 3 |
| concepts[11].score | 0.15437451004981995 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q425681 |
| concepts[11].display_name | Lenalidomide |
| concepts[12].id | https://openalex.org/C87355193 |
| concepts[12].level | 1 |
| concepts[12].score | 0.0 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q411 |
| concepts[12].display_name | Astrobiology |
| concepts[13].id | https://openalex.org/C121332964 |
| concepts[13].level | 0 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q413 |
| concepts[13].display_name | Physics |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9177043437957764 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/internal-medicine |
| keywords[1].score | 0.6951285004615784 |
| keywords[1].display_name | Internal medicine |
| keywords[2].id | https://openalex.org/keywords/dexamethasone |
| keywords[2].score | 0.6050716042518616 |
| keywords[2].display_name | Dexamethasone |
| keywords[3].id | https://openalex.org/keywords/hazard-ratio |
| keywords[3].score | 0.5647751092910767 |
| keywords[3].display_name | Hazard ratio |
| keywords[4].id | https://openalex.org/keywords/carfilzomib |
| keywords[4].score | 0.547812283039093 |
| keywords[4].display_name | Carfilzomib |
| keywords[5].id | https://openalex.org/keywords/refractory |
| keywords[5].score | 0.5126182436943054 |
| keywords[5].display_name | Refractory (planetary science) |
| keywords[6].id | https://openalex.org/keywords/confidence-interval |
| keywords[6].score | 0.512069046497345 |
| keywords[6].display_name | Confidence interval |
| keywords[7].id | https://openalex.org/keywords/multiple-myeloma |
| keywords[7].score | 0.4694152772426605 |
| keywords[7].display_name | Multiple myeloma |
| keywords[8].id | https://openalex.org/keywords/adverse-effect |
| keywords[8].score | 0.45947378873825073 |
| keywords[8].display_name | Adverse effect |
| keywords[9].id | https://openalex.org/keywords/oncology |
| keywords[9].score | 0.4411904811859131 |
| keywords[9].display_name | Oncology |
| keywords[10].id | https://openalex.org/keywords/gastroenterology |
| keywords[10].score | 0.41281723976135254 |
| keywords[10].display_name | Gastroenterology |
| keywords[11].id | https://openalex.org/keywords/lenalidomide |
| keywords[11].score | 0.15437451004981995 |
| keywords[11].display_name | Lenalidomide |
| language | en |
| locations[0].id | doi:10.1007/s12325-021-01884-7 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S27230875 |
| locations[0].source.issn | 0741-238X, 1865-8652 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0741-238X |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Advances in Therapy |
| locations[0].source.host_organization | https://openalex.org/P4310320330 |
| locations[0].source.host_organization_name | Adis, Springer Healthcare |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320330 |
| locations[0].license | cc-by-nc |
| locations[0].pdf_url | https://link.springer.com/content/pdf/10.1007/s12325-021-01884-7.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Advances in Therapy |
| locations[0].landing_page_url | https://doi.org/10.1007/s12325-021-01884-7 |
| locations[1].id | pmid:34561812 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Advances in therapy |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/34561812 |
| locations[2].id | pmh:oai:scholarworks.indianapolis.iu.edu:1805/39836 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306522653 |
| locations[2].source.issn | |
| locations[2].source.type | journal |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | True |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PMC |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].source.host_organization_lineage | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | PMC |
| locations[2].landing_page_url | https://hdl.handle.net/1805/39836 |
| locations[3].id | pmh:oai:pubmedcentral.nih.gov:8523001 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S2764455111 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | PubMed Central |
| locations[3].source.host_organization | https://openalex.org/I1299303238 |
| locations[3].source.host_organization_name | National Institutes of Health |
| locations[3].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Adv Ther |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/8523001 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5003280863 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Thibaud Prawitz |
| authorships[0].affiliations[0].raw_affiliation_string | Evidence Synthesis, Modeling, and Communication Group, Evidera, Paris, France |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Thibaud Prawitz |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Evidence Synthesis, Modeling, and Communication Group, Evidera, Paris, France |
| authorships[1].author.id | https://openalex.org/A5082564837 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-6553-4618 |
| authorships[1].author.display_name | Rakesh Popat |
| authorships[1].countries | GB |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I1340918713, https://openalex.org/I45129253 |
| authorships[1].affiliations[0].raw_affiliation_string | NIHR/UCLH Clinical Research Facility, University College London Hospitals, NHS Foundation Trust, London, UK |
| authorships[1].institutions[0].id | https://openalex.org/I45129253 |
| authorships[1].institutions[0].ror | https://ror.org/02jx3x895 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I124357947, https://openalex.org/I45129253 |
| authorships[1].institutions[0].country_code | GB |
| authorships[1].institutions[0].display_name | University College London |
| authorships[1].institutions[1].id | https://openalex.org/I1340918713 |
| authorships[1].institutions[1].ror | https://ror.org/042fqyp44 |
| authorships[1].institutions[1].type | healthcare |
| authorships[1].institutions[1].lineage | https://openalex.org/I1340918713 |
| authorships[1].institutions[1].country_code | GB |
| authorships[1].institutions[1].display_name | University College London Hospitals NHS Foundation Trust |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Rakesh Popat |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | NIHR/UCLH Clinical Research Facility, University College London Hospitals, NHS Foundation Trust, London, UK |
| authorships[2].author.id | https://openalex.org/A5052787074 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-9445-8781 |
| authorships[2].author.display_name | Attaya Suvannasankha |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I1283055418, https://openalex.org/I4210110049, https://openalex.org/I55769427 |
| authorships[2].affiliations[0].raw_affiliation_string | Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN, USA |
| authorships[2].institutions[0].id | https://openalex.org/I1283055418 |
| authorships[2].institutions[0].ror | https://ror.org/01aaptx40 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I1283055418, https://openalex.org/I4388446366, https://openalex.org/I592451 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Indiana University Health |
| authorships[2].institutions[1].id | https://openalex.org/I55769427 |
| authorships[2].institutions[1].ror | https://ror.org/05gxnyn08 |
| authorships[2].institutions[1].type | education |
| authorships[2].institutions[1].lineage | https://openalex.org/I55769427, https://openalex.org/I592451 |
| authorships[2].institutions[1].country_code | US |
| authorships[2].institutions[1].display_name | Indiana University – Purdue University Indianapolis |
| authorships[2].institutions[2].id | https://openalex.org/I4210110049 |
| authorships[2].institutions[2].ror | https://ror.org/01zpmbk67 |
| authorships[2].institutions[2].type | healthcare |
| authorships[2].institutions[2].lineage | https://openalex.org/I1322918889, https://openalex.org/I2799886695, https://openalex.org/I4210110049, https://openalex.org/I4210127612, https://openalex.org/I4388446366, https://openalex.org/I592451 |
| authorships[2].institutions[2].country_code | US |
| authorships[2].institutions[2].display_name | Richard L. Roudebush VA Medical Center |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Attaya Suvannasankha |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN, USA |
| authorships[3].author.id | https://openalex.org/A5044352141 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-5536-8038 |
| authorships[3].author.display_name | Grammati Sarri |
| authorships[3].affiliations[0].raw_affiliation_string | Evidence Synthesis, Modeling, and Communication Group, Evidera, The Ark, 201 Talgarth Rd, Hammersmith, London, W6 8BJ, UK |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Grammati Sarri |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Evidence Synthesis, Modeling, and Communication Group, Evidera, The Ark, 201 Talgarth Rd, Hammersmith, London, W6 8BJ, UK |
| authorships[4].author.id | https://openalex.org/A5011839706 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-5922-9764 |
| authorships[4].author.display_name | Rachel Hughes |
| authorships[4].affiliations[0].raw_affiliation_string | Evidence Synthesis, Modeling, and Communication Group, Evidera, San Francisco, CA, USA |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Rachel Hughes |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Evidence Synthesis, Modeling, and Communication Group, Evidera, San Francisco, CA, USA |
| authorships[5].author.id | https://openalex.org/A5036882362 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Feng Wang |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I196272386, https://openalex.org/I4210114143 |
| authorships[5].affiliations[0].raw_affiliation_string | Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA |
| authorships[5].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[5].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[5].institutions[1].id | https://openalex.org/I196272386 |
| authorships[5].institutions[1].ror | https://ror.org/00rxpqe74 |
| authorships[5].institutions[1].type | education |
| authorships[5].institutions[1].lineage | https://openalex.org/I196272386 |
| authorships[5].institutions[1].country_code | US |
| authorships[5].institutions[1].display_name | Providence College |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Feng Wang |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA |
| authorships[6].author.id | https://openalex.org/A5029729610 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-0686-2395 |
| authorships[6].author.display_name | Cosmina Hogea |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I196272386, https://openalex.org/I4210114143 |
| authorships[6].affiliations[0].raw_affiliation_string | Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA |
| authorships[6].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[6].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[6].institutions[0].type | company |
| authorships[6].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[6].institutions[1].id | https://openalex.org/I196272386 |
| authorships[6].institutions[1].ror | https://ror.org/00rxpqe74 |
| authorships[6].institutions[1].type | education |
| authorships[6].institutions[1].lineage | https://openalex.org/I196272386 |
| authorships[6].institutions[1].country_code | US |
| authorships[6].institutions[1].display_name | Providence College |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Cosmina Hogea |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA |
| authorships[7].author.id | https://openalex.org/A5027761623 |
| authorships[7].author.orcid | https://orcid.org/0009-0003-0052-4832 |
| authorships[7].author.display_name | Shannon Ferrante |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I196272386, https://openalex.org/I4210114143 |
| authorships[7].affiliations[0].raw_affiliation_string | Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA |
| authorships[7].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[7].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[7].institutions[0].type | company |
| authorships[7].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[7].institutions[1].id | https://openalex.org/I196272386 |
| authorships[7].institutions[1].ror | https://ror.org/00rxpqe74 |
| authorships[7].institutions[1].type | education |
| authorships[7].institutions[1].lineage | https://openalex.org/I196272386 |
| authorships[7].institutions[1].country_code | US |
| authorships[7].institutions[1].display_name | Providence College |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Shannon Allen Ferrante |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA |
| authorships[8].author.id | https://openalex.org/A5024291639 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-6977-0220 |
| authorships[8].author.display_name | Boris Gorsh |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I196272386, https://openalex.org/I4210114143 |
| authorships[8].affiliations[0].raw_affiliation_string | Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA |
| authorships[8].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[8].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[8].institutions[0].type | company |
| authorships[8].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[8].institutions[1].id | https://openalex.org/I196272386 |
| authorships[8].institutions[1].ror | https://ror.org/00rxpqe74 |
| authorships[8].institutions[1].type | education |
| authorships[8].institutions[1].lineage | https://openalex.org/I196272386 |
| authorships[8].institutions[1].country_code | US |
| authorships[8].institutions[1].display_name | Providence College |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Boris Gorsh |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA |
| authorships[9].author.id | https://openalex.org/A5076517089 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Jenny Willson |
| authorships[9].countries | GB |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[9].affiliations[0].raw_affiliation_string | Value Evidence and Outcomes, GlaxoSmithKline, London, UK |
| authorships[9].institutions[0].id | https://openalex.org/I188950975 |
| authorships[9].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[9].institutions[0].type | company |
| authorships[9].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[9].institutions[0].country_code | GB |
| authorships[9].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Jenny Willson |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Value Evidence and Outcomes, GlaxoSmithKline, London, UK |
| authorships[10].author.id | https://openalex.org/A5006367261 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-4147-0549 |
| authorships[10].author.display_name | Venediktos Kapetanakis |
| authorships[10].affiliations[0].raw_affiliation_string | Evidence Synthesis, Modeling, and Communication Group, Evidera, The Ark, 201 Talgarth Rd, Hammersmith, London, W6 8BJ, UK |
| authorships[10].author_position | last |
| authorships[10].raw_author_name | Venediktos Kapetanakis |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Evidence Synthesis, Modeling, and Communication Group, Evidera, The Ark, 201 Talgarth Rd, Hammersmith, London, W6 8BJ, UK |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://link.springer.com/content/pdf/10.1007/s12325-021-01884-7.pdf |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10649 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2720 |
| primary_topic.subfield.display_name | Hematology |
| primary_topic.display_name | Multiple Myeloma Research and Treatments |
| related_works | https://openalex.org/W2526451291, https://openalex.org/W2912170340, https://openalex.org/W4318915818, https://openalex.org/W2981119906, https://openalex.org/W2063424779, https://openalex.org/W2088635940, https://openalex.org/W2887253292, https://openalex.org/W2192430028, https://openalex.org/W3214088986, https://openalex.org/W2563047534 |
| cited_by_count | 10 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 2 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 2 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 3 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 3 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1007/s12325-021-01884-7 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S27230875 |
| best_oa_location.source.issn | 0741-238X, 1865-8652 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0741-238X |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Advances in Therapy |
| best_oa_location.source.host_organization | https://openalex.org/P4310320330 |
| best_oa_location.source.host_organization_name | Adis, Springer Healthcare |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320330 |
| best_oa_location.license | cc-by-nc |
| best_oa_location.pdf_url | https://link.springer.com/content/pdf/10.1007/s12325-021-01884-7.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Advances in Therapy |
| best_oa_location.landing_page_url | https://doi.org/10.1007/s12325-021-01884-7 |
| primary_location.id | doi:10.1007/s12325-021-01884-7 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S27230875 |
| primary_location.source.issn | 0741-238X, 1865-8652 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0741-238X |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Advances in Therapy |
| primary_location.source.host_organization | https://openalex.org/P4310320330 |
| primary_location.source.host_organization_name | Adis, Springer Healthcare |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320330 |
| primary_location.license | cc-by-nc |
| primary_location.pdf_url | https://link.springer.com/content/pdf/10.1007/s12325-021-01884-7.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Advances in Therapy |
| primary_location.landing_page_url | https://doi.org/10.1007/s12325-021-01884-7 |
| publication_date | 2021-09-24 |
| publication_year | 2021 |
| referenced_works | https://openalex.org/W2549396793, https://openalex.org/W2889850156, https://openalex.org/W1999549312, https://openalex.org/W3001391389, https://openalex.org/W2588220165, https://openalex.org/W1988265934, https://openalex.org/W2460376887, https://openalex.org/W2921533600, https://openalex.org/W2995934717, https://openalex.org/W2184270030, https://openalex.org/W2650689221, https://openalex.org/W2758779514, https://openalex.org/W2969931905, https://openalex.org/W2987028072, https://openalex.org/W2005947177, https://openalex.org/W2486629951, https://openalex.org/W2785372400, https://openalex.org/W2918524720, https://openalex.org/W3044244229, https://openalex.org/W2416614764, https://openalex.org/W2202939373, https://openalex.org/W2974976384, https://openalex.org/W4245689579, https://openalex.org/W2416607799, https://openalex.org/W1577036326 |
| referenced_works_count | 25 |
| abstract_inverted_index | |
| cited_by_percentile_year.max | 97 |
| cited_by_percentile_year.min | 94 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 11 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.5 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.79392783 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |